Long-term visit-to-visit glycemic variability as predictor of micro- and macrovascular complications in patients with type 2 diabetes: The Rio de Janeiro Type 2 Diabetes Cohort Study
Open accessThe DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Abstract
Long-term visit-to-visit glycemic variability is an additional measure of glycemic control. We aimed to evaluate the prognostic value of several measures of glycemic variability for the occurrence of micro- and macrovascular complications, and all-cause mortality in patients with type 2 diabetes. 654 individuals were followed-up over a median of 9.3 years. Glycemic variability (SDs and coefficients of variation of HbA 1c and fasting glycaemia) was measured during the first 12- and 24-months. Multivariate Cox analysis, adjusted for risk factors and mean HbA 1c and fasting glycaemia levels, examined the associations between glycemic variability and the occurrence of microvascular (retinopathy, microalbuminuria, renal function deterioration, peripheral neuropathy) and macrovascular complications [total cardiovascular events (CVE), major adverse CVEs (MACE) and cardiovascular mortality], and of all-cause mortality. During follow-up, 128 patients had a CVE (96 MACE), and 158 patients died (67 from cardiovascular diseases); 152 newly-developed or worsened diabetic retinopathy, 183 achieved the renal composite outcome (89 newly developed microalbuminuria and 91 deteriorated renal function), and 96 newly-developed or worsened peripheral neuropathy. Glycemic variability, particularly the 24-month parameters either estimated by HbA 1c or by fasting glycemia, predicted all endpoints, except for retinopathy and peripheral neuropathy development/progression, and was a better predictor than mean HbA 1c . Glycemic variability predicted retinopathy development/progression in patients with good glycemic control (HbA 1c ≤ 7.5%, 58 mmol/mol) and predicted new-incident peripheral neuropathy. Long-term visit-to-visit glycemic variability is an additional and frequently a better glycemic parameter than mean HbA 1c levels for assessing the risk of future development of micro- and macrovascular complications in patients with type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Importantly, the CKD-EPI equation has been updated to a new version that is race agnostic and termed CKD-EPI 2021.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [397]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Standards of Medical Care in Diabetes
Power, D. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1593 · Cited by 8,673
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Monnier, L., Mas, E., Ginet, C., Michel, F., Villon, L., Cristol, J.-P., & Colette, C. (2006) · JAMA · doi:10.1001/jama.295.14.1681 · Cited by 2,444 · cited 1×
“Acute, short-term glycemia fluctuations induce superoxide overproduction, increased oxidative stress, inflammatory cytokines generation and endothelial dysfunction and damage [11, 53, 54], all linked to chronic diabetic complications.”
BackgroundCeriello, A., Esposito, K., Piconi, L., Ihnat, M. A., Thorpe, J. E., Testa, R., Boemi, M., & Giugliano, D. (2008) · Diabetes · doi:10.2337/db08-0063 · Cited by 1,310 · cited 1×
“Acute, short-term glycemia fluctuations induce superoxide overproduction, increased oxidative stress, inflammatory cytokines generation and endothelial dysfunction and damage [11, 53, 54], all linked to chronic diabetic complications.”
BackgroundThe Diabetes Control and Complications Trial Research Group (1995) · Diabetes · doi:10.2337/diab.44.8.968 · Cited by 1,301
Diabetes: a 21st century challenge
Zimmet, P. Z., Magliano, D. J., Herman, W. H., & Shaw, J. E. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70112-8 · Cited by 1,062 · cited 1×
“Background Type 2 diabetes is an important public health problem worldwide, not only by its increasing prevalence, but also because its associated micro- and macrovascular complications severely impact on individuals’ quality of life and pose a great burden on healthcare systems [1, 2].”
BackgroundFollow-up of glycemic control and cardiovascular outcomes in type 2 diabetes
Hayward, R. A., Reaven, P. D., Wiitala, W. L., Bahn, G. D., Reda, D. J., Ge, L., McCarren, M., Duckworth, W. C., & Emanuele, N. V. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414266 · Cited by 668
Follow-up of blood-pressure lowering and glucose control in type 2 diabetes
Zoungas, S., Chalmers, J., Neal, B., Billot, L., Li, Q., Hirakawa, Y., Arima, H., Monaghan, H., Joshi, R., Colagiuri, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407963 · Cited by 626 · cited 1×
“0% (69–64 mmol/mol) actually reduces such risk [7, 8].”
BackgroundLong-term Glycemic Variability and Risk of Adverse Outcomes: A Systematic Review and Meta-analysis
Gorst, C., Kwok, C. S., Aslam, S., Buchan, I., Kontopantelis, E., Myint, P. K., Heatlie, G., Loke, Y., Rutter, M. K., & Mamas, M. A. (2015) · Diabetes Care · doi:10.2337/dc15-1188 · Cited by 530 · cited 7×
“Alternatively, but not excluding, increased glycemic variability might simply be a marker of unstable glycemic control due to poor treatment adherence and self-management patient compliance [12, 31], multimorbidity, poor quality of life and lack of social support, and frequent infections complications [12].”
BackgroundResultInfluential
Cited by
Lu, J., Ma, X., Zhou, J., Zhang, L., Mo, Y., Ying, L., Lu, W., Zhu, W., Bao, Y., Vigersky, R. A., et al. (2018) · Diabetes Care · doi:10.2337/dc18-1131 · Cited by 517
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Elafros, M. A., Andersen, H., Bennett, D. L., Savelieff, M. G., Viswanathan, V., Callaghan, B. C., & Feldman, E. L. (2022) · The Lancet Neurology · doi:10.1016/s1474-4422(22)00188-0 · Cited by 387
Glycemic variability: adverse clinical outcomes and how to improve it?
Zhou, Z., Sun, B., Huang, S., Zhu, C., & Bian, M. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01085-6 · Cited by 255
“In the Rio De Janeiro Type 2 Diabetes Cohort Study, 24-month visit-to-visit FPG variability was a significant risk predictor for renal outcomes, and 24-month visit-to-visit HbA1c variability was a better risk predictor for diabetic retinopathy progression than HbA1c levels [31].”
BackgroundAdvances in Screening, Early Diagnosis and Accurate Staging of Diabetic Neuropathy
Carmichael, J., Fadavi, H., Ishibashi, F., Shore, A. C., & Tavakoli, M. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.671257 · Cited by 176
“In the follow-up study of T2DM (a median of 9.3 years), mean HbA1c levels were the main risk predictor for the composite outcome of developing or worsening diabetic neuropathy, whereas glycemic variability assessed by HbA1c variability was a better risk predictor for new incident of neuropathy (36).”
BackgroundInfluential
Metadata
- Authors
- Cardoso, C. R. L., Leite, N. C., Moram, C. B. M., & Salles, G. F.
- Affiliations
- Universidade Federal do Rio de Janeiro (BR)
- Corresponding author
- Salles, G. F.
- Venue
- Cardiovascular Diabetology
- Published
- 2018-02-24
- Volume
- 17
- Issue
- 1
- Pages
- 33-33
- ISSN
- 1475-2840 (ISSN-L)
- PMC
- PMC6389075
- OpenAlex
- W2804490349
- Cited by
- 222
- References
- 67
- Citations by year
- 2026: 7 · 2025: 17 · 2024: 55 · 2023: 21 · 2022: 29 · 2021: 24 · 2020: 38 · 2019: 23 · 2018: 8
- FWCI
- 18.51
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Cardiovascular Diabetology (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Fundação Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- glycemic variability, type 2 diabetes, microvascular complications, macrovascular complications, HbA1c, fasting blood glucose, diabetic retinopathy, microalbuminuria, diabetic nephropathy, peripheral neuropathy, cardiovascular events, major adverse cardiovascular events, cardiovascular mortality, all-cause mortality, prognostic factors, glycemic control
- MeSH terms
- Aged, Albuminuria, Blood Glucose, Brazil, Cause of Death, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Diabetic Nephropathies, Diabetic Neuropathies, Diabetic Retinopathy, Female, Glycated Hemoglobin, Humans, Male, Middle Aged, Predictive Value of Tests, Prognosis, Prospective Studies, Risk Factors, Time Factors, Biomarkers, Disease Progression, Risk Assessment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long-term visit-to-visit glycemic variability as predictor of micro- and macrovascular complications in patients with type 2 diabetes: The Rio de Janeiro Type 2 Diabetes Cohort Study. https://app.cochat.ai/papers/10.1186/s12933-018-0677-0
- The paper
- Cardoso, C. R. L., Leite, N. C., Moram, C. B. M., & Salles, G. F. (2018). Long-term visit-to-visit glycemic variability as predictor of micro- and macrovascular complications in patients with type 2 diabetes: The Rio de Janeiro Type 2 Diabetes Cohort Study. Cardiovascular Diabetology. https://doi.org/10.1186/s12933-018-0677-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.